VLS Valneva SE

VALNEVA - Declaration of shares and voting rights: May 31, 2024

VALNEVA - Declaration of shares and voting rights: May 31, 2024

VALNEVA

Declaration of shares and voting rights

May 31, 2024

__________________________________________________________________________________________

Company name: VALNEVA

Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)

Regulated market of Euronext Paris - Compartment B

Declaration date: June 4, 2024

Number of shares

composing the share capital of Valneva		Total number of voting rights including suspended voting rights*Description of the change Date on which this change was recognizedTotal number of voting rights excluding suspended voting rights**
 139,276,901



ordinary shares with a par value of €0.15 each





158,390,665Double voting rights granted on 5,743 ordinary sharesBetween May 3 &

May 18, 2024		158,266,343

___________________________

* Theoretical voting rights. This number is used as the basis for calculating threshold crossings. In accordance with Article 223-11 of the AMF General Regulations, this number is calculated on the basis of all shares to which voting rights are attached, including those for which voting rights have been suspended.

** Net (or exercisable at a General Meeting) voting rights.

Attachment



EN
04/06/2024

Underlying

VLSValneva SE

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Valneva SE

Bruno Bulic ... (+2)
  • Bruno Bulic
  • Oscar Haffen Lamm
VLS VALNEVA SE

Valneva: Ixchiq label extension to include adolescents

Valneva today announced that it will seek, as expected, a label extension for its Chikungunya vaccine Ixchiq in Europe and Canada, to now also include age group 12 to 17 years. The vaccine is currently approved in Europe, US and Canada for individuals 18 years of age and older. The label extension

09/18/24 September 18, 2024 1 EN
 PRESS RELEASE
Free
VLS VALNEVA SE

Valneva Submits Label Extension Applications for its Chikungunya Vacci...

Valneva Submits Label Extension Applications for its Chikungunya Vaccine, IXCHIQ®, to EMA and Health Canada   To potentially include adolescents and antibody persistence up to two years Saint Herblain (France), September 18, 2024 – (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that it has submitted label extension applications to the European Medicines Agency (EMA) and Health Canada to potentially expand the use of its chikungunya vaccine, IXCHIQ®, to adolescents aged 12 to 17 years in Europe and Canada. The Canadian label extension application also inc...

September 18, 2024 1 EN
Ana Arjona-Martinez ... (+3)
  • Ana Arjona-Martinez
  • Chaima Ferrandon
  • Sven Edelfelt
FP TOTAL SE
EQNR EQUINOR ASA
DG VINCI SA
GALP GALP ENERGIA SGPS SA CLASS B
FGR EIFFAGE SA
VRAP VRANKEN-POMMERY MONOPOLE SA
VETO VETOQUINOL SA
VLS VALNEVA SE
TRI TRIGANO SA
ENI ENI S.P.A.
REP REPSOL SA
SESL SES-IMAGOTAG SA
BP. BP P.L.C.
SHEL SHELL PLC
09/13/24 September 13, 2024 1 EN
Ana Arjona-Martinez ... (+3)
  • Ana Arjona-Martinez
  • Chaima Ferrandon
  • Sven Edelfelt
FP TOTAL SE
EQNR EQUINOR ASA
DG VINCI SA
GALP GALP ENERGIA SGPS SA CLASS B
FGR EIFFAGE SA
VRAP VRANKEN-POMMERY MONOPOLE SA
VETO VETOQUINOL SA
VLS VALNEVA SE
TRI TRIGANO SA
ENI ENI S.P.A.
REP REPSOL SA
SESL SES-IMAGOTAG SA
BP. BP P.L.C.
SHEL SHELL PLC
09/13/24 September 13, 2024 1 FR
Bruno Bulic ... (+2)
  • Bruno Bulic
  • Oscar Haffen Lamm
VLS VALNEVA SE

Valneva successfull EUR 61m capital increase

Valneva today announced the issuing of 22.6m new ordinary shares at a 15% discount to last trading price, translating into EUR 61.2m fresh capital.Valneva indicated that the funds will be allocated to development of the clinical program (Ixchiq Phase III pediatric and Phase IV) and progression into

09/13/24 September 13, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch